Sen-Jam Pharmaceutical has launched a Phase II trial in Australia to evaluate SJP-001, a novel hangover prevention therapy combining naproxen and fexofenadine.
Sen-Jam Pharmaceutical initiates a Phase II trial in Australia to evaluate SJP-001, a novel combination of naproxen and fexofenadine, for hangover prevention.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.